News reports from Europe are confirming that Schering-Plough is acquiring Organon BioSciences (OBS), the parent company of Intervet, from Akzo Nobel, in a move that could create a new leader in the globalanimal health industry. The deal, said to be worth 11 billion Euros ($14.4bn), was announced on Monday from the Netherlands headquarters of Schering-Plough.
The deal may place Schering-Plough at the top of animal health corporations worldwide by sales.
One of Schering-Plough’s most familiar equine-market products is the anti-inflammatory Banamine. Intervet makes several widely-used vaccines, plus wormers like Panacur and specialty treatments like Regumate.
Read the press release from the Schering-Plough web site here.
